Carlson Caspers represents Teva in this Paragraph IV Hatch-Waxman case concerning Teva’s ANDA for capecitabine (Xeloda®), which challenged the infringement and validity of the listed Orange Book patents.  This case settled on favorable terms on the eve of trial.